Physician profile
Stuart D Spalding
NPI 1184680068
$4,254.89
in general payments reported to CMS, 2019-2025
32 companies · $709 in 2025
The $709 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $394 · 2021: $257 · 2022: $224 · 2023: $807 · 2024: $776 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $484.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $439.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $433.10 | 2019-2025 | |
| Lilly USA, LLC | $393.39 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $336.66 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $331.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $256.07 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Sanofi-Aventis U.S. LLC | $228.02 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.56 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $149.08 | 2022-2025 | |
| Amarin Pharma, INC. | $125.78 | 2019-2020 | |
| Astellas Pharma US INC | $97.52 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $92.60 | 2019-2021 | |
| Medtronic, INC. | $80.49 | 2025 | Synchromedii |
| Allergan, INC. | $78.87 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.50 | 2019-2025 | Capvaxive, Gardasil 9 |
| Dynavax Technologies Corporation | $57.04 | 2024-2025 | Heplisav-B |
| Abbott Laboratories | $46.62 | 2022-2024 | Freestyle Libre 3, Freestyle Libre |
| Idorsia Pharmaceuticals US INC | $44.66 | 2023 | Quviviq |
| Exact Sciences Corporation | $42.15 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $39.93 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $33.52 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $30.64 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $30.46 | 2021-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $30.39 | 2019-2023 | |
| Boston Scientific Corporation | $27.67 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.39 | 2022 | |
| Esperion Therapeutics, INC. | $17.94 | 2020 | |
| Insulet Corporation | $14.80 | 2025 | Omnipod |
| Dexcom, INC. | $14.22 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $13.54 | 2019 | |
| Shire North American Group INC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Spalding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.